Manufacturing Intelligence for CDMO Teams
Start each day with curated headlines on CDMO capacity, regulatory signals, and supply-chain moves — then read weekly deep dives that explain what changed structurally and how sponsors should adjust shortlists.
Feed: /api/seo/feed · Markdown mirrors: /posts/<slug>.md
- Daily newsCDMO Daily News — July 24, 2026
- ImmuPharma Selects Thermo Fisher for Kapiglucagon Drug-Product CDMO Services
- SK pharmteco Advances AAV Gene Therapy to Phase III with 20 Clinical Batches for Genethon DMD Program
- Restore Vision Selects Forge Biologics for RV-001 AAV Gene Therapy Manufacturing
- Deep diveCDMO biologics capacity and manufacturing bottlenecks: navigating capacity constraints
Biologics manufacturing capacity lags demand by a structural margin, forcing pharma to prioritize CDMO partnership flexibility over technical credentials alone while emerging technologies like membrane-based processing and continuous manufacturing offer near-term relief without major capital investment. Policy reform and workforce develop
- Daily newsCDMO Daily News — July 19, 2026
- OXB Expands AAV Manufacturing with Plowshare Therapies Gene Therapy Deal
- Daily newsCDMO Daily News — July 17, 2026
- BriaCell Selects FUJIFILM Biotechnologies California for Bria-IMT Phase 3 and Commercial Manufacturing
- OXB Secures AAV Manufacturing Contract with Plowshare Therapies
- Merck Opens €25M BioReliance Testing Facility in Darmstadt, Germany
- Cytovance Biologics Adds Perfusion Capabilities to Upstream Process Development
- Deep diveBIOSECURE Act CDMO supply chain risk: 5-10% annual capacity tightening
BIOSECURE Act restrictions are triggering a genuine 5–10% annual capacity contraction among compliant CDMOs through 2026, forcing sponsors into costly supply-chain audits and premium pricing as they compete for scarce manufacturing slots with zero China exposure across their entire vendor networks.
- Daily newsCDMO Daily News — July 11, 2026
- FDA Proposes Streamlined Registration for Distributed Manufacturing and Foreign Drug Suppliers
- FDA FRAME Initiative Establishes Regulatory Framework for Advanced Manufacturing Technologies
- Daily newsCDMO Daily News — July 4, 2026
- FDA PreCheck Pilot Selects Seven Companies to Expand U.S. Drug Manufacturing Capacity
- Deep diveAPI CDMOs Navigate Geopolitical Risk: Dual Sourcing & Supply Resilience in 2026
The active pharmaceutical ingredient (API) manufacturing landscape is undergoing a structural realignment driven by geopolitical fragmentation and supply-chain vulnerability. As 2026 approaches, the traditional "make versus buy" calculus has fundamentally shifted. Pharmaceutical companies now weigh strategic control, risk tolerance, and regulatory…
- Daily newsCDMO Daily News — July 1, 2026
- AGC Biologics Expands US Fill-Finish via Pyramid Pharma Partnership
- Cytiva Doubles Logan, UT Liquid Media Capacity with New ADCF Facility
- Daily newsCDMO Daily News — June 24, 2026
- EMA Convenes AI in GMP Workshop to Shape Annex 22 Guidance on Adaptive Models
- Deep dive503B Outsourcing Facilities & FDA Drug Shortages: Can CDMOs Close the Supply Gap?
- Daily newsCDMO Daily News — June 15, 2026
- CCRM's OmniaBio Partners with Avectas to Advance Automated Cell Therapy Manufacturing
- Daily newsCDMO Daily News — June 11, 2026
- Scinai Completes Recipharm Israel Acquisition, Expands CDMO Platform to Two Sites
- Deep diveSterile Biologics Capacity Crunch: How to Secure CDMO Slots in 2026
- Daily newsCDMO Daily News — June 9, 2026
- Cell & Gene Therapy CDMOs Address Manufacturing Complexity and Capacity Gaps
- Single-Site Operations and Integrated Teams Reduce CDMO Partnership Risk
- Daily newsCDMO Daily News — June 6, 2026
- Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1
- Neuronoff Implants First Patient in DOD-Funded Trial of Injectrode® for Neurogenic Bladder in Spinal Cord Injury
- WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility